Published online Nov 21, 2017. doi: 10.3748/wjg.v23.i43.7705
Peer-review started: August 15, 2017
First decision: August 30, 2017
Revised: September 27, 2017
Accepted: September 28, 2017
Article in press: September 28, 2017
Published online: November 21, 2017
Processing time: 97 Days and 18.5 Hours
Obesity-associated nonalcoholic fatty liver disease (NAFLD) is characterized by excessive deposition of fat in hepatocytes. The saturated free fatty acid palmitate, the concentration of which is often elevated in obesity, is a major contributor to an increase in intrahepatic triglyceride. G0/G1 switch gene 2 (G0S2) plays an important role in regulating hepatic lipid metabolism. However, the role of G0S2 and its transcriptional regulation in palmitate-induced hepatic lipid accumulation has remained unclear.
This study was carried out to clarify the molecular mechanism connecting palmitate to obesity-associated NAFLD. As CCAAT/enhancer binding protein beta (C/EBPβ), proliferator-activated receptor gamma (PPARγ) and G0S2 all relate to obesity-associated NAFLD, we investigated their roles and interrelationships in palmitate-induced hepatic lipid accumulation. The results lead to important new insights into the molecular mechanism of NAFLD.
The goal of this study was to determine the role of G0S2 and its transcriptional regulation in palmitate-induced hepatic lipid accumulation. The results suggest a previously unknown link between C/EBPβ and G0S2 that contributes to hepatic steatosis.
In this study, we examined lipolysis, lipid accumulation, and the expression of C/EBPβ, PPARγ and PPARγ-regulated genes (G0S2, GPR81, GPR109A and Adipoq) in response to palmitate treatment in HepG2 cells. Specifically, we investigated the relationships between expression of the aforementioned proteins and hepatocyte lipolysis and lipid accumulation by using siRNA-mediated gene knockdown experiments.
Palmitate significantly facilitated lipid accumulation and suppressed lipolysis in HepG2 cells. Palmitate also significantly increased the expression of C/EBPβ, PPARγ, and PPARγ target genes (G0S2, GPR81, GPR109A and Adipoq). C/EBPβ knockdown significantly reduced palmitate-induced PPARγ and G0S2 expression. Moreover, C/EBPβ knockdown attenuated lipid accumulation and augmented lipolysis in palmitate-treated HepG2 cells. Importantly, G0S2 knockdown significantly attenuated lipid accumulation and augmented lipolysis in palmitate-treated HepG2 cells, while G0S2 knockdown had no efects on palmitate-induced expression of C/EBPβ, PPARγ, and PPARγ target genes (GPR81, GPR109A, and Adipoq).
Palmitate can induce lipid accumulation in HepG2 cells by activating C/EBPβ-mediated G0S2 expression. The result provides novel evidence linking G0S2 expression to palmitate-induced hepatic lipogenesis. Considering that liver lipid accumulation is not only a hallmark of NAFLD, but also the first and critical step in the initiation and progression of NAFLD, interfering with G0S2 may represent an effective strategy for the treatment of obesity-related hepatic steatosis.